Global Information
회사소개 | 문의 | 위시리스트

약제 분석 : Cyramza(사이람자)

Cyramza

리서치사 Datamonitor Healthcare
발행일 2019년 09월 상품 코드 603933
페이지 정보 영문 65 Pages
가격
US $ 10,000 ₩ 11,798,000 PDF by E-mail (Single User License)


약제 분석 : Cyramza(사이람자) Cyramza
발행일 : 2019년 09월 페이지 정보 : 영문 65 Pages

항VEGFR2 완전 인간 모노클로널 IgG1 항체인 Cyramza(사이람자)에 대해 조사했으며, 주요 국가/지역의 매출 실적과 예측, 질환별 약제 평가·SWOT 분석 및 약제 개요 등을 정리하여 전해드립니다.

  • 제품 개요
  • Cyramza(사이람자) : 대장암(CRC)
  • Cyramza(사이람자) : 간세포암(HCC)
  • Cyramza(사이람자) : 방광암
  • Cyramza(사이람자) : 비소세포폐암(NSCLC)
  • Cyramza(사이람자) : 위암
KSA 18.02.28

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Drug Overview:

Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Cyramza: Hepatocellular carcinoma (HCC)
    • Cyramza: Non-small cell lung cancer (NSCLC)
    • Cyramza: Gastric cancer
    • Cyramza: Colorectal cancer (CRC)
    • Cyramza: Bladder cancer

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Cyramza for HCC
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Cyramza for HCC
  • Figure 3: Cyramza sales for HCC across the US, Japan, and five major EU markets, by country, 2018-27
  • Figure 4: Cyramza for non-small cell lung cancer - SWOT analysis
  • Figure 5: Datamonitor Healthcare's drug assessment summary for Cyramza in non-small cell lung cancer
  • Figure 6: Datamonitor Healthcare's drug assessment summary for Cyramza in non-small cell lung cancer
  • Figure 7: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 8: Cyramza for gastric cancer - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Cyramza for gastric cancer
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Cyramza for gastric cancer
  • Figure 11: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 12: Cyramza for colorectal cancer - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • Figure 15: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Cyramza for urothelial bladder cancer - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary for Cyramza in urothelial bladder cancer
  • Figure 18: Datamonitor Healthcare's drug assessment summary for Cyramza in urothelial bladder cancer

LIST OF TABLE

  • Table 1: Recent high-impact events for Cyramza in HCC
  • Table 2: Cyramza drug profile
  • Table 3: Approval history of Cyramza for HCC in the US, Japan, and five major EU markets
  • Table 4: Trials of Cyramza for HCC
  • Table 5: Cyramza for HCC - SWOT analysis
  • Table 6: Cyramza drug profile
  • Table 7: Cyramza pivotal trial data in non-small cell lung cancer
  • Table 8: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 9: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Cyramza patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 11: Cyramza drug profile
  • Table 12: Cyramza pivotal trial data in gastric cancer
  • Table 13: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 14: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 15: Cyramza drug profile
  • Table 16: Cyramza Phase III data in colorectal cancer
  • Table 17: Cyramza Phase I trials in colorectal cancer
  • Table 18: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 19: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 20: Cyramza drug profile
  • Table 21: Cyramza Phase III trial in urothelial bladder cancer
  • Table 22: Cyramza early-phase data in urothelial bladder cancer
Back to Top
전화 문의
F A Q